Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1
5(62.5%)
Phase 2
3(37.5%)
8Total
Phase 1(5)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT06845553Phase 2Recruiting

A Study to Assess the Efficacy and Safety of Vutiglabridin in Knee Osteoarthritis Patients

Role: lead

NCT06329141Phase 2Recruiting

A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients

Role: lead

NCT05642377Phase 1Recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HGR4113 in Healthy Subjects

Role: lead

NCT05310032Phase 1Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses

Role: lead

NCT05197556Phase 2Completed

A Study to Evaluate the Safety and Efficacy of HSG4112 in Overweight and Obese Patients

Role: lead

NCT04703764Phase 1Completed

A Study to Investigate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of HSG4112

Role: lead

NCT04732988Phase 1Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Food Effect of HSG4112

Role: lead

NCT04733001Phase 1Completed

A Study to Investigate the Effect of Food on the Pharmacokinetics of HSG4112

Role: lead

All 8 trials loaded